Galaxy Diagnostics

Galaxy Diagnostics is an infectious disease testing company founded by researchers at NC State University College of Veterinary Medicine, specializing in PCR-based detection of Bartonella and other difficult-to-diagnose pathogens. The company's flagship product, the Bartonella ePCR test, combines proprietary enrichment culture with PCR methods to provide highly sensitive detection of Bartonella species, addressing the limitations of traditional serology and standard PCR testing for these stealth-adaptive pathogens. Galaxy Diagnostics offers diversified in vitro diagnostic tests for infectious diseases, with clinical genomics capabilities including amplification-based PCR diagnostics. The company's enrichment culture methodology enhances pathogen detection by growing low-level infections to detectable concentrations before PCR analysis, significantly improving sensitivity for chronic and relapsing infections that are difficult to diagnose through standard testing approaches. Founded in 2009 and headquartered in Durham, North Carolina, the company has raised approximately $9.7M in Series A funding from investors including HHS and First Flight Venture Center. Galaxy Diagnostics differentiates itself through its proprietary enrichment culture combined with PCR methodology for highly sensitive Bartonella detection, addressing diagnostic challenges for stealth-adaptive pathogens that evade standard testing approaches.